MANTA Ultrasound Closure Study

Inclusion Criteria: * Candidate for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter valve replacement (TAVR) via a 10-20F device or sheath (12-25F OD) with common femoral artery approach * Vessel size would allow for access for the MANTA VCD based on vessel size as determined by baseline CTA: minimum vessel diameter of 5mm for the 14F MANTA VCD and 6mm for the 18F MANTA VCD * Understand and sign the study specific written informed consent form and PHI authorization * Able and willing to fulfill the follow-up requirements Exclusion Criteria: * Patients known to be pregnant or lactating * Patients who have a systemic infection or a local infection at or near the access site * Patients with significant anemia (hemoglobin ≤10 g/DL) * Patients who are morbidly obese or cachectic (BMI \>40 or \<20kg/m2) * Patients with a known bleeding disorder including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand disease * Patients with allergy to bovine materials or any other device material, including collagen and/or collagen products, polyglycolic or polylactic acid, stainless steel or nickel * Patients with a femoral artery puncture in target groin within the prior 30 days, prior vascular closure device placement in the target common femoral artery within 3 months, or any prior target femoral artery access-related complication * Patients who have undergone use of an intra-aortic balloon pump (IABP) through…